期刊文献+

原发性醛固酮增多症诊断切点的研究及临床应用 被引量:11

Determination of optimal cut-off point for primary aldosteronism and its diagnostic value in clinical practice
下载PDF
导出
摘要 目的探讨原发性醛固酮增多症(primary aldosteronism,PA)患者立卧位醛固酮、醛固酮/肾素比值(ratio of aldosterone/rennin,ARR)的诊断切点,提高PA诊断的准确率。方法收集2006-2014年在我院诊断的PA患者45例及年龄相匹配的原发性高血压患者(essential hypertension,EH)50例。PA患者均行病理诊断,其中34例术后病理证实为肾上腺醛固酮腺瘤,11例为肾上腺皮质增生。患者均行血钾、24 h尿钾、立卧位肾素、血管紧张素Ⅱ、醛固酮、皮质醇节律、儿茶酚胺代谢产物等检测,计算ARR,利用受试者工作曲线(ROC)得到诊断PA立卧位醛固酮、ARR的最佳切点,评价不同指标诊断PA的敏感性及特异性。并比较两种不同病理结果间醛固酮及ARR的差异。结果 PA组与EH组间性别、年龄和血压无明显差异,PA组肾素活性、血钾显著低于EH组,而醛固酮、ARR及24 h尿钾均显著高于EH组。诊断PA的立位醛固酮的最佳切点为0.221 ng/m L,敏感性(Sen)=0.561,特异性(Spe)=0.909;卧位醛固酮为0.175 ng/m L,Sen=0.829,Spe=0.795;立位ARR为19.5(ng·d L-1)/(ng·m L-1·h-1),Sen=0.878,Spe=0.955;卧位ARR为20.5(ng·d L-1)/(ng·m L-1·h-1),Sen=0.902,Spe=0.841。在PA组中肾上腺醛固酮腺瘤的ARR较肾上腺皮质增生患者高,尤其立位ARR最为明显。结论立位醛固酮、ARR诊断PA的敏感性较卧位差,但特异性较强,所以临床对高血压患者行上述激素检查时应综合立卧位激素的检查结果,且其水平与病理有关。 Objective To determine the cut-off points for supine and upright plasma levels of aldosterone (ALD) and for ratio of ALD/rennin (ARR) in primary aldosteronism (PA), and investigate their diagnostic values to improve the diagnostic accuracy of the disease. Methods Clinical data of 45 patients of pathologically confirmed PA and 50 age- and gender-matched patients of essential hypertension (EH) admitted in our hospital from 2006 to 2014 were collected in this study. Histological examination indicated that 34 PA patients were confirmed as adrenal adenoma and 11 as adrenal cortical hyperplasia. Serum potassium, and 24- hour urinary potassium, corticosteroid rhythm, catecholamine metabolites, and supine and upright plasma levels of rennin, angiotensin Ⅱ and ALl) were measured. Moreover, the levels of ALD and ARR were analyzed to draw the receiver operating characteristic (ROC) curve and obtain the optimal cut-off points, and access the sensitivities and specificities of those indexes. Besides, the difference of ALl) and ARR were compared between 2 kinds of pathological types of PA. Results There was no obvious difference in gender, age and blood pressure between PA and EH groups. Serum potassium and plasma renin activity were lower in PA thanin EH group, but ALD ARR and 24-hour urinary potassium were higher. The optimal cut-off point of uptight plasma ALD was 0.221 ng/mL, with a sensitivity of 0. 561 and specificity of 0.909, that of supine plasma ALD was 0. 175 ng/mL with a sensitivity of 0. 829 and specificity of 0. 795, that of uptight ARR was 19.5 (ng·dL^-1 )/(ng·mL^-1·h^-1 ) with a sensitivity of 0. 878 and specificity of 0. 955, and that of supine ARR was 20.5 (ng·dL^-1 )/(ng·mL^-1·h^-1) with a sensitivity of 0.902 and specificity of 0. 841. ARR was higher in patients with adrenal adenoma than those with adrenal cortex hyperplasia, especially the uptight ARR. Conclusion The upright ALD and ARR have lower sensitivity than the supine ones, but higher specificity. So clinician should comprehensively consider the hormone test results on both supine and uptight positions for hypertensive patients, moreover the results are associated with pathologic characteristics.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2015年第11期1146-1149,共4页 Journal of Third Military Medical University
基金 重庆市科技攻关课题(CSTC2012gg-yyjs100062)~~
关键词 原发性醛固酮增多症 醛固酮 醛固酮/肾素 诊断切点 肾上腺醛固酮腺瘤 肾上腺皮质增生 primary aldosteronism aldosterone aldosterone/renin cut-off point adrenal adenomaaldosterone adrenal cortex hyperplasia
  • 相关文献

参考文献15

  • 1Velasco A, Vongpatanasin W. The evaluation and treatment of endocrine forms of hypertension[J]. Curr Cardiol Rep, 2014, 16(9): 528.
  • 2Ducher M, Mounier-Vehier C, Baguet J P, et al. Aldosterone-to-renin ratio for diagnosing aldosterone-producing adenoma: a multicentre study[J]. Arch Cardiovasc Dis, 2012, 105(12): 623-630.
  • 3徐媛媛,蒋怡然,苏颋为,蔡剑飞,叶俊娜,宁光,王卫庆.醛固酮/肾素比值在原发性醛固酮增多症筛查中的临床价值[J].中华内分泌代谢杂志,2012,28(4):301-305. 被引量:21
  • 4Savard S, Amar L, Plouin P F, et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study[J]. Hypertension, 2013, 62(2): 331-336.
  • 5Milliez P, Girerd X, Plouin P F, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism[J]. J Am Coll Cardiol, 2005, 45(8): 1243-1248.
  • 6Turchi F, Ronconi V, di-Tizio V, et al. Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment[J]. Nutr Metab Cardiovasc Dis, 2014, 24(5): 476-482.
  • 7Stehr C B, Mellado R, Ocaranza M P, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients[J]. J Hypertens, 2010, 28(10): 2120- 2126.
  • 8Bernini G, Galetta F, Franzoni F, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism[J]. J Hypertens, 2008, 26(12): 2399-2405.
  • 9Jansen P M, van-den-Born B H, Frenkel W J, et al. Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism[J]. J Hypertens, 2014, 32(1): 115-126.
  • 10刘力生.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-708. 被引量:6935

二级参考文献51

共引文献6952

同被引文献84

  • 1曾正陪.内分泌性高血压的现状及诊治[J].临床内科杂志,2006,23(3):149-152. 被引量:18
  • 2陈国伟,郑宗锷.现代心脏内科学[M].湖南:湖南科学技术出版社.1995:960.
  • 3Hafner S, Baumert J, Emeny RT, et al. Hypertension and de- pressed symptom - atology : a cluster related to the activation of the renin - angiotensin - aldosteronesystem ( RAAS ). Findings from population based KORA F4 study[J]. Psycho -neuroendocrinolo- gy, 2013, 38(10): 2065-2074.
  • 4Born - Frontsberg E, Reincke M, Rump LC, et al. Cardiovascular and cerebrovascula comorbidities of hypokalemic and normokalemic primary aldosteronism ; results of the German Conn' s registry[ J]. J Clin Endoerinol Metab, 2009, 94(4) : 1125 -1130.
  • 5Schut AF, Bleumink GS, Stricker BH, et al. Angiotensin coverting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects[J]. Eur Heart J, 2004, 25(23) : 2143 - 2148.
  • 6Kofodziejczyk - Kruk S, Januszewicz W, P6czkowska M, et al. Pri- mary aldosteronism - recent progress and current concepts [ J ]. En- dokrynol Pol, 2013, 64(4) : 312 -318.
  • 7Corbin F, Douville P, Lebel M. Active renin mass concentration todetermine aldosterone - to - renin ratio in screening for primary al- dosteronism[ J]. Int J Nephrol Renovasc Dis, 2011, 4( 1 ) : 115 - 120.
  • 8Pilz S, Kienreich K, Gaksch M, et al. Aldosterone to active Renin ratio as screening test for primary aldosteronism:reproducibility and influence of orthostasis and salt loading [ J ]. Horm Metab Res, 2014, 46(6) : 427 -432.
  • 9Jenny M, Evelyn F, Anna D, et al. Clinical validation for the aldo- sterone - to - renin ratio and aldosterone suppression testing using simultaneous fully antomated chemiluminescence immunoassays [J]. JHypert, 2015, 33(1): 1 -12.
  • 10Michel A, Joel M. Measurement of plasma renin: a critical review of methodology[ J]. J Renin Angiotensin Aldostemne Syst, 2010, 11(2): 89-90.

引证文献11

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部